Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chloroquine
Drug ID BADD_D00440
Description Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054]
Indications and Usage For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Marketing Status Not Available
ATC Code P01BA01
DrugBank ID DB00608
KEGG ID D02366
MeSH ID D002738
PubChem ID 2719
TTD Drug ID D09EGZ
NDC Product Code Not Available
Synonyms Chloroquine | Chlorochin | Chingamin | Khingamin | Nivaquine | Chloroquine Sulfate | Sulfate, Chloroquine | Chloroquine Sulphate | Sulphate, Chloroquine | Aralen | Arequin | Arechine
Chemical Information
Molecular Formula C18H26ClN3
CAS Registry Number 54-05-7
SMILES CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.005--
Corneal opacity06.06.03.005--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000466%
Deafness neurosensory17.04.07.001; 04.02.01.002--Not Available
Delirium19.13.02.001--
Delusion19.10.01.0010.000466%
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.000466%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.000932%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Dyskinesia17.01.02.006--
Dyspnoea22.02.01.004; 02.01.03.0020.001165%
Electrocardiogram QRS complex13.14.05.034--Not Available
Electrocardiogram QRS complex prolonged13.14.05.0030.001398%Not Available
Electrocardiogram QT prolonged13.14.05.0040.000699%
Eosinophilia01.02.04.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Generalised anxiety disorder19.06.01.0040.000466%Not Available
Generalised tonic-clonic seizure17.12.01.0020.000699%Not Available
Haemolysis01.06.04.0020.001398%
Hallucination19.10.02.002--
Hallucination, auditory19.10.02.0030.000466%Not Available
Hallucination, tactile19.10.02.0080.000466%Not Available
Hallucinations, mixed19.10.02.0070.000466%Not Available
Headache17.14.01.0010.000932%
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages